SignaCor Email Formats

Biotechnology Research • Belfast, N. Ireland, United Kingdom • 1-10 Employees

Key Contact at SignaCor

Chris Watson

Founder & CEO

Company overview

Headquarters	Belfast, N. Ireland, United Kingdom
Website	signacor.co.uk
NAICS	541714
Founded	2024
Employees	1-10

About SignaCor

SignaCor is a clinical stage, drug development company, spun-out from Queen’s University Belfast, dedicated to the treatment of cardiac disease. At SignaCor, we are pioneering a first-in-class therapeutic approach to symptomatic hypertrophic cardiomyopathy (HCM)—one that goes beyond symptom management to target the underlying disease pathology. Cardiaza is the first and only treatment that harnesses DNA methylation to address multiple underlying causes of symptomatic HCM, including established fibrosis, a key driver of disease progression. Ph2a Clinical Trial commencing in 2025.

Employees by Management Level

Total employees: 1-10

Seniority

Employees

C-Suite

Employees by Department

SignaCor has 1 employees across 1 departments.

Departments

Number of employees

Funding Data

SignaCor has never raised funding before.

Frequently asked questions

SignaCor is located in Belfast, N. Ireland, GB.

SignaCor was founded in 2024, making it 2 years old. The company has established itself as a significant player in its industry over this time.

SignaCor has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at SignaCor

Chris Watson

Founder & CEO

4.8

40,000 users